GlassScriptPhysician profile
Christopher Michael Galloway
NPI 1346613718
$4,544.96
in general payments reported to CMS, 2019-2025
31 companies · $876 in 2025
The $876 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,109 · 2022: $523 · 2023: $1,017 · 2024: $1,019 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,913.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $560.32 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $474.88 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Gilead Sciences, INC. | $371.46 | 2021-2025 | |
| Uswm, LLC | $323.70 | 2021-2023 | Lucemyra, Zimhi |
| Pfizer INC. | $282.67 | 2023-2025 | |
| Braeburn INC. | $247.41 | 2023-2025 | Brixadi |
| Optinose US, INC. | $237.59 | 2021 | |
| Harmony Biosciences LLC | $225.72 | 2023-2025 | Wakix |
| Takeda Pharmaceuticals U.S.A., INC. | $215.11 | 2021-2023 | Trintellix |
| Indivior INC. | $192.53 | 2024-2025 | Sublocade |
| Idorsia Pharmaceuticals US INC | $150.16 | 2022-2023 | Quviviq |
| Horizon Therapeutics Plc | $137.22 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $135.13 | 2023-2024 | Rexulti |
| Alkermes, INC. | $116.51 | 2021-2023 | Vivitrol |
| Exact Sciences Corporation | $113.72 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $108.27 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $84.32 | 2021 | |
| Antares Pharma, INC. | $77.64 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceutical Holding Company LTD. | $72.28 | 2022 | |
| Medtronic, INC. | $59.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.94 | 2021 | |
| Viiv Healthcare Company | $43.70 | 2024-2025 | Apretude |
| Supernus Pharmaceuticals, INC. | $42.70 | 2024 | Qelbree |
| Jazz Pharmaceuticals INC. | $40.97 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $33.70 | 2023 | Horizant |
| Vertex Pharmaceuticals Incorporated | $31.03 | 2025 | |
| Amgen INC. | $26.88 | 2025 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $26.71 | 2021 | |
| Echosens North America, INC. | $23.58 | 2025 | Fibroscan |
| Teva Pharmaceuticals USA, INC. | $20.14 | 2022 | |
| Hologic Sales and Service, LLC | $15.73 | 2024 | Aptima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Galloway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.